Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MNC and MSC in Spastic Cerebral Palsy
NCT03795974Phase 2Unknown
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2017
- Primary completion
- Oct 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of umbilical cord blood mononuclear cells and mesenchymal stem cells in spastic cerebral palsy, sponsored by Tehran University of Medical Sciences. Primary endpoint: Gross Motor Function Classification System at 12 months. Status: unknown.
02
Drugs
umbilical cord blood mononuclear cellsmesenchymal stem cells
03
Conditions
spastic cerebral palsy
Beyond the preview
Go deeper on NCT03795974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795974.